CARLSBAD, Calif.--(BUSINESS WIRE)--The Immune Response Corporation (OTCBB: IMNR), an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases, announced that Dr. Joseph O'Neill, President and CEO, will present an overview of the Company’s immune-based therapies, currently in Phase II clinical trials, at the Rodman & Renshaw Eighth Annual Healthcare Conference in New York City.

The Company’s presentation to the investment community will take place on Tuesday, November 7, 2006, at 3:55 p.m. (EST).

A live webcast of this presentation will be available at http://www.wsw.com/webcast/rrshq10/imnr/. The online replay will be available for 90 days after the presentation.

Dr. O’Neill will discuss a key strategic agreement, signed October 10, 2006, with Accelsiors CRO & Consultancy Services, a clinical research organization (CRO) with extensive experience in conducting multiple sclerosis (MS) trials, to oversee a 200-patient Phase IIb trial of NeuroVax™, an investigational T-cell receptor (TCR) peptide vaccine for the treatment of multiple sclerosis (MS). He will review in detail the Company’s drug development pipeline, and status of the Phase II clinical trials in progress for NeuroVax, and for IR103, for the treatment of human immunodeficiency virus (HIV). IR103 is based on the Company’s patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk.

“By harnessing the body’s own defenses to control disease, NeuroVax and IR103 potentially offer important clinical advances for patients suffering from MS and HIV.” said Dr. O’Neill. “We continue to make significant strides in the development of these immune based therapies and are optimistic that they may benefit the millions of patients in need of more effective and tolerable treatment options.”

http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20061030005853&newsLang=en